CAJ | 학술논문

近年来淋巴瘤的发病率逐渐上升,已经成为最常见的恶性肿瘤之一.新的化疗方案、单克隆抗体、小分子靶向药物等治疗方式已经显著改善了淋巴瘤患者的生存.但是,淋巴瘤患者出现复发或耐药的比例仍然很高,因此针对这些患者寻找新的治疗方式至关重要.细胞免疫治疗可以通过引发特异有效的抗肿瘤免疫反应杀灭肿瘤.继承性细胞免疫疗法、免疫调节药物、免疫检查点治疗等免疫治疗方式在复发/难治淋巴瘤患者的治疗中取得了显著的疗效,逐渐开启了淋巴瘤治疗的新时代.
근년래림파류적발병솔축점상승,이경성위최상견적악성종류지일.신적화료방안、단극륭항체、소분자파향약물등치료방식이경현저개선료림파류환자적생존.단시,림파류환자출현복발혹내약적비례잉연흔고,인차침대저사환자심조신적치료방식지관중요.세포면역치료가이통과인발특이유효적항종류면역반응살멸종류.계승성세포면역요법、면역조절약물、면역검사점치료등면역치료방식재복발/난치림파류환자적치료중취득료현저적료효,축점개계료림파류치료적신시대.
Over the past years, the incidence of lymphoma has been increasing, which has become one of the most common cancers around the world.The survival of lymphoma patients has been significantly improved due to advances of therapeutic methods such as new chemotherapy regimens, monoclonal antibodies and small molecular targeted drugs.However, the number of patients with relapsed/refractory lymphoma still account for a large proportion.It is of great significance to find new ways to treat these patients.Cellular immunotherapy could kill tumor cells by causing specific and effective antitumor immune response.Remarkable advances have been made in immunotherapy, such as adoptive immunotherapy, immune checkpoint inhibitors and immunomodulation therapy, for relapsed/refractory lymphoma patients, which will gradually open a new era in the treatment of lymphoma.